ABSTRACT
Objective To investigate the effect of somatostatin on the electrophysiological changes of early diabetic rats,and to clarify its therapeutic effects on retinopathy in early diabetic rats.Methods 20 Wistar male rats, which were induced into diabetic rat models by intraperitoneal injection of streptozotocin (STZ),were randomly divided into somatostatin therapy group and model control group, 10 in each group.The rats in somatostatin therapy group were injected with somatostatin 10μg·kg-1 ·d-1,for 8 weeks;the rats in model control group received the same volume of saline.Another 10 male Wistar rats were used as normal control group.The changes of blood glucose and electroretinogram were measured, and the indicators were used for statistical analysis. Results Compared with model control group,the blood glucose was declined in somatostatin therapy group at the 8th week (P0.05).Conclusion Somatostatin has a therapeutic effect on early diabetic retinopathy in rats.
ABSTRACT
Objective To compare the efficacy and safety of glargine(Lantus) versus biphasic insulin aspart 30 (30% free and 70% protamine-bound, BIAsp 30) after continuous subcutaneous insulin infusion treatment (CSII) in newly diagnosed type 2 diabetes mellitus. Methods A 20 week open and random study was performed. All 60 patients with newly diagnosed T2DM were randomly divided into two groups. Group B patients was treated by glargine and group A received treatment with BIAsp 30 administered immediately before dinner and breakfast. Blood glucose at 7 time points, glycosylated hemoglobin A1c(HbA1c) and hypoglycemia were observed. Results The postprandial glucose(PPG) was significantly lower in group B than in group A (P<0.05), and the frequency of hypoglycaemic episodes was lower in group B than in group A (P<0.05). The fasting blood glucose(FBG) was not different between two groups (P>0.05). And there was no difference between two groups in HbA1c and other adverse events. Conclusions Glargine is surperior to BIAsp30, not only in controlling the PPG but also in reducing the incidence of hypoglycemia.
ABSTRACT
Objective To report a new approach of splenic hilar lymph nodes dissection in radical gastrectomy for gastric cancer. Methods 193 cases of gastric cancer patient receiving radical resection of gastric cancer between May 2008 and October 2008 were studied. The tail and body of spleen and pancreas were thoroughly freed with retroperitoneal way retrogressively and extruded out of abdominal cavity in 80 cases. The other 113 cases received operation with routine way. Results In 80 cases who received operation with retroperitoneal approach retrogressively, the total splenic hilar lymph nodes were 519, the positive ones were 65, the positive rate was 12.5 %; In the other 113 cases the total splenic hilar lymph nodes were 565, the positive ones were 58, the positive rate was 10.3 %. The positive rate had statistic significance between these two groups. Conclusion Extruded splenic hilar lymph nodes dissection with retroperitoneal approach retrogressively is safe and has the same effect with splenectomy in gastric cancer operation.